Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Snowshoe who wrote (1431)	12/8/1999 7:49:00 AM
From: kendall harmon	Read Replies (1) \| Respond to of 1754

VISX is trading up in Europe this morning: finance.uk.yahoo.com Current exchange rate for the euro is about 1.03 which gives a price of 56ish

To: Snowshoe who wrote (1431)	12/8/1999 12:07:00 PM
From: Brian Sullivan	Read Replies (1) \| Respond to of 1754

Insurance won't typically cover any of the costs associated with elective eye correction, so you typically have to pay the entire cost yourself. You can however enroll in a Heath Care reimbursement account and use pre-tax dollars to pay for the costs. I was on the sidelines waiting for this ruling and I bought in yesterday at 49 7/16. This ruling by the administrative law judge was not entirely unexpected. Last month I sold out of VISX in my IRA account and decided to wait for this ruling as I expected to see the stock correct significantly if the ruling went against the company. However the ruling changes nothing about this stock. They were only trying to expedite their patent enforcement against Nidek and this was the end run play to do that. With the unfavorable ruling they will just have to use the normal slower US courts to enforce their patents. That said I still look for VISX to cut some deal with Bausch and Lomb since they want very badly to get in the eye corrective surgery business. Announcement to a patent license deal with BOL could be the news that puts VISX back up to 100 per share.